Journal
JOURNAL OF NUTRITIONAL BIOCHEMISTRY
Volume 31, Issue -, Pages 38-44Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jnutbio.2015.12.001
Keywords
Huntington's disease; Biomarkers; Metabolomics; Amino acid; Phosphatidylcholine; Phospholipase A(2); PCYT1A
Funding
- Academia Sinica [AS-100-TP2-B02-4]
- Chang Gung Memorial Hospital, Taoyuan, Taiwan [CMRPG3E142, 3D009]
Ask authors/readers for more resources
Huntington's disease (HD), caused by expanded CAG repeats encoding a polyglutamine tract in the huntingtin protein, presents with a predominant degeneration of neurons in the striatum and cortex. Although a few studies have identified substantial metabolite alterations in plasma, the picture of plasma metabolomics of HD has not been clearly depicted yet. Using a global metabolomics screening for plasma from 15 HD patients and 17 controls, HD patient group was separated from the control group by a panel of metabolite's belonging to carnitine, amino acid and phosphatidylcholine species. The quantification of 184 related metabolites (including carnitine, amino acid and phosphatidylcholine species) in 29 HD patients, 9 presymptomatic HD carriers and 44 controls further showed one up-regulated (glycine) and 9 down-regulated metabolites (taurine, serotonin, valine, isoleucine, phosphatidylcholine acyl-alkyl 06:0 and 04:0 and lysophosphatidylcholine acyl C20:3). To understand the biosynthetic alterations of phosphatidylcholine in HD, we examined the expression levels and activities of a panel of key enzymes responsible for phosphatidylcholine metabolism. The results showed down-regulation of PCYT1A and increased activity of phospholipase A(2) in HD leukocytes. These metabolic profiles strongly indicate that disturbed metabolism is involved in pathogenesis of HD and provide clue for the development of novel treatment strategies for HD. (C) 2015 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available